Hansa Biopharma announces key executive appointments to support continued growth

Sandra Frithiof brings over 25 years of experience in human resources in different industries, to Hansa. Most recently, Sandra was HR Director at Ayvens Sweden AB, a global leader in the mobility sector. Prior to Ayvens, Sandra was VP Human Resources at Calliditas Therapeutics, where she built the Global HR organization to support the company's entry into the US market. Previously, Sandra was Head of HR and COO at Ramberg Advokater, a Swedish law firm and earlier in her career, Sandra held HR positions at Karolinska University Hospital, UTC, CGI and Manpower Group. Sandra has a bachelor's degree in human resource management from Örebro University, Sweden. Ms Frithiof will replace Anne Säfström Lanner, CHRO, who will leave the organization.

Sandra Frithiof brings over 25 years of experience in human resources in different industries, to Hansa. Most recently, Sandra was HR Director at Ayvens Sweden AB, a global leader in the mobility sector. Prior to Ayvens, Sandra was VP Human Resources at Calliditas Therapeutics, where she built the Global HR organization to support the company's entry into the US market. Previously, Sandra was Head of HR and COO at Ramberg Advokater, a Swedish law firm and earlier in her career, Sandra held HR positions at Karolinska University Hospital, UTC, CGI and Manpower Group. Sandra has a bachelor's degree in human resource management from Örebro University, Sweden. Ms Frithiof will replace Anne Säfström Lanner, CHRO, who will leave the organization.

Brian Gorman and Sandra Frithiof will report to CEO Renée Aguiar-Lucander and be members of the Executive Committee.

Kerstin Falck Lagercrantz will join Hansa from Pfizer AB, where she has spent over 20 years in various positions in corporate affairs and commercial operations. Between 2014-2022, Kerstin held the role of Corporate Affairs Director where she was responsible for external communications, patient affairs, corporate social responsibility and crisis and issues management. During this time, she successfully implemented agreements and influenced several health policies during the COVID-19 pandemic. In addition, Kerstin has held several positions with SwedenBIO, including member of the board, and multiple roles with LIF (Swedish Pharmaceutical Industry Association). She has a Degree of Bachelor of Science in Business Administration and Economics, from Uppsala University, Sweden. Ms Falck Lagercrantz will report to Maria Törnsén, Chief Operating Officer and US President, and she replaces Stephanie Kenney, former VP Corporate Affairs, who has left Hansa.

"We are very pleased to welcome Brian, Sandra and Kerstin to Hansa. They bring invaluable experience in their respective areas of expertise, which will be critical as we step up our US pre-commercial activities, subject to data from two Phase 3 readouts and our first BLA submission" said CEO Renée Aguiar-Lucander.

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
[email protected]

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-announces-key-executive-appointments-to-support-continued-growth,c4212214

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-announces-key-executive-appointments-to-support-continued-growth-302516363.html